Research library
A curated set of peer-reviewed, PubMed-indexed publications that places the compounds in our catalog in their scientific context — assembled for research reference only, not as a claim of safety or efficacy.
A reading list, not a results list
This library curates key peer-reviewed publications and clinical data that underpin the scientific research context for the compounds available from Chemyo. Every reference is drawn from indexed, peer-reviewed journals accessible through PubMed or by direct journal publication, and each entry links straight to its PubMed abstract so you can read the source rather than take our word for it.
We assembled it for a specific reason. Chemyo is a US-based supplier of research-grade SARMs, nootropics, and metabolic reference compounds for laboratory and research use, and a researcher choosing a reference compound should be able to find the literature behind it in one place. That is all this page does — it points to the published record. It does not summarise, interpret, or endorse any finding, and it makes no claim about what any compound does in humans.
Read this first. This library is provided for research reference only — nothing here constitutes a claim of safety or efficacy for human use. All Chemyo products are strictly for laboratory and research use, and are not for human or veterinary consumption, diagnosis, or treatment. The full terms are set out in our research use disclaimer.
What earns a place on this page
Inclusion here is about provenance, not promotion. A study is listed because it is part of the published record for a compound — never because of what it appears to show.
Peer-reviewed and indexed
Only work published in peer-reviewed journals and indexed in PubMed is listed. Each entry links to the PubMed abstract so the source is one click away.
Tied to a catalog compound
Each reference maps to a specific compound we stock and is grouped by its mechanism — androgen receptor, metabolic, GH axis, or cognitive — so the literature stays easy to navigate.
Reported neutrally
Listings keep the authors, year, title, and journal as published. We do not paraphrase conclusions or extract claims — reading and interpreting the study is the researcher’s job.
Consistent with our standards
The same evidence-first discipline that governs our editorial standards applies here: cite the primary source, and never let a label outrun the data.
Literature by compound
Grouped by mechanism, covering the SARMs, metabolic, GH-axis, and nootropic compounds in our catalog. Every link opens a PubMed abstract.
SARMs: selective androgen receptor modulators
MK-2866 (Ostarine / Enobosarm)
- Dalton JT, et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. Journal of Cachexia, Sarcopenia and Muscle, 2(3), 153–161. PubMed
- Dobs AS, et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. The Lancet Oncology, 14(4), 335–345. PubMed
LGD-4033 (Ligandrol)
- Basaria S, et al. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. The Journals of Gerontology, 68(1), 87–95. PubMed
- Roch PJ, et al. (2020). Clinical and biochemical investigation of a case of anabolic androgenic steroid use combined with the selective androgen receptor modulator LGD-4033. Frontiers in Pharmacology, 11, 622546. PubMed
RAD-140 (Testolone)
- Miller CP, et al. (2011). Design, synthesis, and preclinical characterization of the selective androgen receptor modulator (SARM) RAD140. ACS Medicinal Chemistry Letters, 2(2), 124–129. PubMed
- Jayaraman A, et al. (2014). Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats. Endocrinology, 155(4), 1398–1406. PubMed
YK-11
- Kanno Y, et al. (2013). Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression. Biological and Pharmaceutical Bulletin, 36(9), 1460–1465. PubMed
- Kanno Y, et al. (2018). (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a selective androgen receptor modulator with androgenic, anabolic, and osteogenic effects. Journal of Pharmacological Sciences, 137(2), 209–216. PubMed
Metabolic compounds: PPARδ and Rev-ErbA agonists
GW501516 (Cardarine)
- Dressel U, et al. (2003). The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Molecular Endocrinology, 17(12), 2477–2493. PubMed
- Narkar VA, et al. (2008). AMPK and PPARδ agonists are exercise mimetics. Cell, 134(3), 405–415. PubMed
SR9009 (Stenabolic)
- Woldt E, et al. (2013). Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine, 19(8), 1039–1046. PubMed
- Sulli G, et al. (2018). Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature, 553(7688), 351–355. PubMed
GH axis: MK-677 (Ibutamoren)
MK-677 (Ibutamoren)
- Nass R, et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine, 149(9), 601–611. PubMed
- Copinschi G, et al. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278–286. PubMed
Nootropics and cognitive research compounds
Noopept (GVS-111)
- Ostrovskaya RU, et al. (2007). The nootropic and neuroprotective proline-containing dipeptide noopept restores spatial memory and increases immunoreactivity to amyloid in an Alzheimer’s disease model. Journal of Psychopharmacology, 21(6), 611–619. PubMed
- Ostrovskaya RU, et al. (2014). Neuroprotective effect of novel cognitive enhancer noopept on AD-related cellular model involves the attenuation of apoptosis and tau hyperphosphorylation. Journal of Biomedical Science, 21(1), 74. PubMed
NSI-189
- Fava M, et al. (2016). A phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients. Molecular Psychiatry, 21(10), 1372–1380. PubMed
NMN (Nicotinamide Mononucleotide)
- Mills KF, et al. (2016). Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism, 24(6), 795–806. PubMed
- Yoshino J, et al. (2011). Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), 528–536. PubMed
How to work with these references
All references link to their PubMed abstracts. Full-text access to the original articles may require institutional journal access or subscription. These references are provided to enable researchers to verify the scientific context of our compound descriptions and to identify relevant literature for their own research programs.
To match a citation to what we stock, browse the catalog by format and compound class. The androgen-receptor and metabolic compounds above sit in our solutions and powders categories, and the full range is in the shop. To understand how we work and who writes our research content, see the about page.
Disclaimer. This library is for research reference only. Nothing here constitutes medical advice or a claim of safety or efficacy for human use. All Chemyo products are for laboratory research use only. See our research use disclaimer.
Find the compound behind the citation
Browse the catalog by format, or read how every batch is documented before it ships.